Cited in:


This article has been cited by:

  1. 1
    Yeong-Liang Lin, Ya-Chi Wu, Guei-Feng Tsai, Electrocardiographic monitoring for QT prolongation in patients treated with ziprasidone—A claims database approach, Pharmacoepidemiology and Drug Safety, 2009, 18, 9
  2. 2
    Jean-François Cadranel, Mimouna Seddik, Sylvia Loric, Sandrine Jeanne, Statines : quelle hépatotoxicité et quelle surveillance?, La Presse Médicale, 2009, 38, 5, 717


  3. 3
    Mihai Daniel Onofrei, Kristina L. Butler, Dawn C. Fuke, Heather B. Miller, Safety of Statin Therapy in Patients with Preexisting Liver Disease, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008, 28, 4
  4. 4
    Elena Tragni, Alessandro Filippi, Giampiero Mazzaglia, Emiliano Sessa, Claudio Cricelli, Alberico L. Catapano, Monitoring statin safety in primary care, Pharmacoepidemiology and Drug Safety, 2007, 16, 6
  5. 5
    Aline Charabaty Pishvaian, Bradley W. Trope, James H. Lewis, Drug-induced liver disease in 2003, Current Opinion in Gastroenterology, 2004, 20, 3, 208


  6. 6
    Current awareness: Pharmacoepidemiology and drug safety, Pharmacoepidemiology and Drug Safety, 2003, 12, 7
  7. 7
    Stephen H. Caldwell, Jeffrey S. Zaidman, Elizabeth E. Hespenheide, The liver and statin drug therapy: uncertain navigation in the sea of risk-benefit, Pharmacoepidemiology and Drug Safety, 2003, 12, 4